Part I. Genomics, Cancer Targets, Transcriptomics, and Gene Expression Analysisn n Genomic Resources for Cancer Biologistsn Xuefeng Bruce Ling, Gene Cutler, and Timothy Hoeyn n Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotypingn Heiko Hermekingn n Identification of Novel Cancer Target Antigens Utilizing EST and Genome Sequence Databasesn Tapan K. Bera, Kristi A. Egland, B. K. Lee, and Ira Pastann n Tree-Based Cancer Classification and Diagnosis Using Gene Expression Datan Heping Zhangn n From FISH to Proteomics: A Molecular Brush to Define Antitumor Drug Actionn Balanehru Subramanian, Alexander Nakeff, and Frederick Valerioten n Gene Program Signatures for Papillomavirus E2-Mediated Senescence in Cervical Cancer Cells: Finding the Points of No Returnn Sarah S. Williams, Bruce J. Aronow, and Susanne I. Wellsn n Part II. Advances in Proteomic and Enzymatic Cancer-Profiling Technologiesn n Mass-Spectrometry-Based Proteomics for Cancer Biologyn Chen Xu and John R. Yates IIIn n Chemical Proteomics in Drug Developmentn Douglas A. Jeffery, Amos Baruch, and Matthew Bogyon n Proteomics-Based Anticancer Drug Discoveryn K. K. Jainn n Cancer Metabolic Phenotype: Exploiting the Cancer Metabolome in Drug Discoveryn John R. Griffiths and Marion Stubbsn n Focusing Target Discovery and Validation Through Proteogenomics and Molecular Imagingn Lucy A. Carver and Jan E. Schnitzern n Part III. Cancer Target Validation: Cellular Approachesn n RNA Interference: RNAid for Future Therapeutics?n Mustapha Diallo, Katja Schmitz, and Ute Schepersn n Image-Based Assays of Cellular Phenotype for Drug Target Discovery and Validationn Kris F. Sachsenmeier and Jonathan A. Terrettn n Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancern David Ljungman and James C. Cusack, Jr.n n Targeting Apoptosis Pathways for Cancer Therapyn Bharvin K. R. Pateln n Part IV. Cancer Target Validation: Animal Approachesn n Genetically Engineered Mouse Models of Human Cancer for Drug Discovery and Developmentn Rónán C. O'Hagan, Min Wu, William M. Rideout III, Yinghui Zhou, and Joerg Heyern n Unraveling the Complexity of Oncogenesis Through In Vivo Optical Imagingn Pamela Reilly Contagn n Innovative Strategies for Improving Engineered Mouse Models of Human Cancer for Preclinical Developmentn Jeffrey J. Martino and Suzie Chenn n Use of Adenovirus-Mediated Gene Transfer to Facilitate Biological Annotation of Novel Genesn Jeff L. Ellsworth, Andrew Feldhaus, and Steven D. Hughesn n Cancer Biology and Transgenic Technology in the Mouse: Bridging the Functional Gapn Cindy E. McKinney and Cooduvalli S. Shashikantn n Homology-Based Genomic Mining of Growth Factors Implicated in Neoplasia and Nephritides: PDGF-Dn Gary C. Starling, William J. LaRochelle, and Gulshan Aran n Part V. Cancer Prognostics, Diagnostics, and Biomarkersn n Cancer Pharmacogenomics: Predicting Drug Response in the Genomic Eran Brian Z. Ring and Huijun Z. Ringn n Diagnosis and Treatment of Malignancies Using Gene Expression Profilingn Jimmy C. Sung, Alice Y. Lee, and Timothy J. Yeatmann n Implications of Epigenetics for Early Cancer Diagnosis and Preventionn Mukesh Verma and Sudhir Srivastavan n Novel Molecular and Genetic Prognostic Biomarkers in Prostate Cancern Arnab Chakravarti and Gary Guotang Zhain n PSA in Prostate Cancer Diagnosisn Pradip Dattan n Tumor Targets and Biomarkers in Renal Cell Carcinoman Ivar Bleumer and Peter F. A. Muldersn n Part VI. Emerging Approaches to Cancer Therapyn n VI-A. Targeting the Vasculaturen n Tumor Vasculature as a Target for Cancer Therapyn Grzegorz
An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.